Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts

References

• Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860–1873.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, . International staging system for multiple myeloma. J Clin Oncol 2005;23: 3412–3420.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bergsagel PL, Kuehl WM, . Advances in biology of multiple myeloma: clinical applications. Blood 2004;104: 607–618.
   PubMed Web of Science ®Google Scholar
• Zavrski I, Jakob C, Schmid P, . Proteasome: an emerging target for cancer therapy. Anticancer Drugs 2005;16:475–481.
   PubMed Web of Science ®Google Scholar
• San Miguel J, Bladé J, Boccadoro M, . A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006;11:51–61.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S, . Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113–3120.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Stem cell transplant: an effective salvage therapy for multiple myeloma. Leuk Lymphoma 2011;52:1413–1414.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010;51:1178–1187.
   PubMed Web of Science ®Google Scholar
• Chang C, Zhu Y, Tang X, . The anti-proliferative effects of norcantharidin on human HepG2 cells in cell culture. Mol Biol Rep 2011;38:163–169.
   PubMed Web of Science ®Google Scholar
• Huang Y, Liu Q, Liu K, . Suppression of growth of highly-metastatic human breast cancer cells by norcantharidin and its mechanisms of action. Cytotechnology 2009;59:201–208.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Chang WM, Liu YW, . A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells. Chem Biol Interact 2009;181:440–446.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Kuo CD, Tsai YM, . Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells. Anticancer Drugs 2008;19:55–64.
   PubMed Web of Science ®Google Scholar
• Luan J, Duan H, Liu Q, . Inhibitory effects of norcantharidin against human lung cancer cell growth and migration. Cytotechnology 2010;62:349–355.
   PubMed Web of Science ®Google Scholar
• Yang PY, Chen MF, Tsai CH, . Involvement of caspase and MAPK activities in norcantharidin-induced colorectal cancer cell apoptosis. Toxicol In Vitro 2010;24:766–775.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203–208.
   PubMed Web of Science ®Google Scholar
• Lee R, Collins T. Nuclear factor-κB and cell survival: IAPs call for support. Circ Res 2001;88:262–264.
   PubMed Web of Science ®Google Scholar
• Markovina S, Callander NS, O’Connor SL, . Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells. Mol Cancer 2010;10:176–189.
   Web of Science ®Google Scholar
• Kong R, Sun B, Jiang H, . Downregulation of nuclear factor-κB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett 2010;291:90–98.
   PubMed Web of Science ®Google Scholar
• Song XN, Du HF, Yu L, . [Norcantharidin potentialize the chemosensitivity of adriamycin through the NF-κB/IκBα signaling pathway]. Zhonghua Xue Ye Xue Za Zhi 2011;32:809–813.
   PubMedGoogle Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621–681.
   PubMed Web of Science ®Google Scholar
• Singh AT, Ghosh M, Forte TM, . Curcumin nanodisk-induced apoptosis in mantle cell lymphoma. Leuk Lymphoma 2011;52: 1537–1543.
   PubMed Web of Science ®Google Scholar
• Sezer O, Niemöller K, Kaufmann O, . Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Haematol 2001;66:238–244.
   PubMed Web of Science ®Google Scholar
• Markovina S, Callander NS, O’Connor SL, . Bortezomib-resistant nuclear factor-κB activity in multiple myeloma cells. Mol Cancer Res 2008;6:1356–1364.
   PubMed Web of Science ®Google Scholar
• Baldwin AS Jr. The NF-κB and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649–83.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Richardson P, . NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002;277: 16639–16647.
   PubMed Web of Science ®Google Scholar
• Du J, Huo J, Shi J, . Polymorphisms of NF-κB family genes are associated with development of multiple myeloma and treatment outcome in patients undergoing bortezomib-based regimens. Haematologica 2011;96:729–737.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Davis RE, Demchenko Y, . Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115–130.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Fonseca R, Chesi M, . Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 2007;12:131–144.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, . Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 2002;99:4079–4086.
   PubMed Web of Science ®Google Scholar
• Fuchs O. Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Curr Mol Pharmacol 2010;3:98–122.
   PubMedGoogle Scholar
• Vega MI, Martinez-Paniagua M, Jazirehi AR, . The NF-κB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma 2008;49:1982–1994.
   PubMed Web of Science ®Google Scholar
• Yeh CB, Hsieh MJ, Hsieh YH, . Antimetastatic effects of norcantharidin on hepatocellular carcinoma by transcriptional inhibition of MMP-9 through modulation of NF-κB activity. PLoS One 2012;7:e31055.
   PubMed Web of Science ®Google Scholar
• Sung B, Kunnumakkara AB, Sethi G, . Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 2009;8:959–970.
   PubMed Web of Science ®Google Scholar
• Zhang JQ, Dai XL, Meng YF, . [Effect of norcantharidin on the growth control of human myeloma cell line U266 and its mechanism]. J Hebei Med Univ 2010;31:896–899.
   Google Scholar